Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology

Key facts

Sponsor

Sanofi

Principal Investigator

ICD CSD

Sanofi

Intervention

Alfuzosin(drug)

Enrollment

25 enrolled

Eligibility

2-16 years · All sexes

Timeline

2007 – 2009

Study locations (12)

• Sanofi-Aventis Administrative Office, Sofia, Bulgaria
• Sanofi-Aventis Administrative Office, Laval, Canada
• Sanofi-Aventis Administrative Office, Tallinn, Estonia
• Sanofi-Aventis Administrative Office, Mumbai, India
• Sanofi-Aventis Administrative Office, Kuala Lumpur, Malaysia
• Sanofi-Aventis Administrative Office, Warsaw, Poland
• Sanofi-Aventis Administrative Office, Moscow, Russia
• Sanofi-Aventis Administrative Office, Belgrade, Serbia
• Sanofi-Aventis Aministrative Office, Singapore, Singapore
• Sanofi-Aventis Administrative Office, Bratislava, Slovakia
• Sanofi-Aventis Administrative Office, Taipei, Taiwan
• Sanofi-Aventis Administrative Office, Istanbul, Turkey (Türkiye)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Hinman syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT04604951
  Below the Belt: Non-invasive Neuromodulation to Treat Bladder, Bowel, and Sexual Dysfunction Following Spinal Cord Injury
  University of British Columbia
• ACTIVE NOT RECRUITINGNCT04924569
  Continence Care Registry
  Hollister Incorporated

See all trials for Hinman syndrome →